Since the World Health Organization (WHO) declared COVID-19,the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),as a pandemic in March 2020,and more than 117 million people worldwide have been confirmed to have been infected.Scientists,medical professionals,and other stakeholders are racing against time to find and develop effective medicines for COVID-19.However,no drug with high efficacy to treat SARS-CoV-2 infection has been approved.With the increasing popularity of gene therapy,scientists have explored the utilization of small RNAs such as microRNAs (miRNAs) as therapeutics.miRNAs are non-coding RNAs with high affinity for the 3'-UTRs of targeted messenger RNAs (mRNAs).Interactions between host cells and viral genomes may induce the upregulation or downregulation of various miRNAs.Therefore,understanding the expression patterns of these miRNAs and their functions will provide insights into potential miRNA-based therapies.This re-view systematically summarizes the potential targets of miRNA-based therapies for SARS-CoV-2 infec-tion and examines the viability of possible transfection methods.

OBJECTIVES: The CYP2B6 is one of the most polymorphic CYP genes in humans that has the potential to modify the pharmacological and toxicological responses to clinically important drugs such as antimalarial artemisinin and its derivatives. The aim of the study was to determine the frequency of CYP2B6 polymorphisms in Timor malaria endemic area, East Nusa Tenggara, Indonesia where Artemisin-based Combination Therapy (ACT) has been used to treat uncomplicated malaria. METHODS: A total of 109 healthy subjects were participated in this study. CYP2B6*4, *6 and *9 polymorphisms were analyzed using PCR-RFLP to confirm the SNPs prevalence of 516G>T and 785A>G in exon 4 and 5. RESULTS: There were 96 subjects included in the analysis. In the exon 4 of CYP2B6 516G>T, the frequency of the T mutation was 37.5% (39/96), and the wildtype 27.1% (26/96). In the exon 5, CYP2B6 785A>G mutant was detected in 29.2% (28/96) of individuals, and the wildtype allele in 35.4% (34/96). The frequency of CYP2B6*9 (516G>T), CYP2B6*4 (785A>G) and CYP2B6*6 (516G>T and 785A>G) were 40.6%, 29.2% and 22.9%, respectively. The prevalence of these CYP2B6 gene polymorphisms in Timorian ethnic were higher than that in Malay, Han Chinese, Indian, and Egyptian populations. CONCLUSION: The prevalence of these CYP2B6 516G>T and 785A>G polymorphisms in Timorian ethnic is higher than that in other populations. These polymorphisms may affect the metabolism of artemisinin and its derivatives.
Alleles ; Asian Continental Ancestry Group ; Cytochrome P-450 CYP2B6* ; Exons ; Healthy Volunteers ; Humans ; Indonesia* ; Malaria ; Metabolism ; Polymorphism, Single Nucleotide ; Prevalence*